Selecting Prescription Drugs For Affordability Review, Part 3

09/18/2024

Washington State Health Care Authority

Overview

- Brief overview of RCW 70.405.040: Affordability Reviews
- Data Measures For Selecting Drugs for Affordability Review
- Rank the Eligible Drugs
- 2023 Eligible Drug Dashboard Preview
- Next steps and Q&A

Overview



Focus of this presentation

Eligible drug list

Bill Section	Number of Distinct NDCs			
(1) Brand name prescription drugs and biologic products that: **(a) Have a wholesale acquisition cost of $60,000 or more per year or course of treatment lasting less than one year; or**	Brand		238	
	Biologic		93	
	Total		331	
(b) Have a price increase of 15 percent or more in any 12-month period or for a course of treatment lasting less than 12 months, or a 50 percent cumulative increase over three years		15% Increase*	50% Increase*	Both
	Brand	105	21	13
	Biologic	1	0	0
	Total	106	21	13
(2) A biosimilar product with an initial wholesale acquisition cost that is not at least 15 percent lower than the reference biological product	9			
(3) Generic drugs with a wholesale acquisition cost of $100 or more for a 30-day supply or less that has increased in price by 200 percent or more in the preceding 12 months.	2			

*Includes NDCs with both 15% and 50% increase

Eligible Drug List



Brief Overview of RCW 70.405.040: Affordability Reviews

Washington State Health Care Authority

Deciding Whether To Conduct A Review

- The Board shall consider:
  - The class of the prescription drug and whether any therapeutically equivalent prescription drugs are available for sale;
  - Input from relevant advisory groups established pursuant to RCW 70.405.020; and
  - The average patient's out-of-pocket cost for the drug.
- Board can choose up to 24 drugs per year

Data Measures For Selecting Drugs for Affordability Review

Washington State Health Care Authority

Deciding Whether To Conduct A Review

The Board shall consider:



+

- Total plan paid amount
- Total out-of-pocket cost
- Total paid amount
- Average plan paid amount
- Average paid amount
- Patient liability proportion
- Number of people using the prescription drug
- Therapeutic equivalent availability
- Generic availability
- If the drug meets multiple thresholds of the legislative definition

Number of people using the drug

- Definition: The number of patients who had a claim for the prescription drug
- Data Field: Number
- Data source: WA-APCD
- Methodology: The count of distinct individuals who had a claim for the prescription drug in 2022

Number of people using the drug

Category	N Obs	N	Minimum	5th Pctl	Median	95th Pctl	Maximum	Mean
Biosimilar not at least 15% lower	9	5	2	2	15	1310	1310	320
Brand or biologic >= 15% increase	106	78	1	1	19	3005	67355	1621
Brand or biologic >= 50% increase	21	15	1	1	30	41939	41939	2863
Course of treatment $60,000 or more	331	226	1	1	27.5	1831	7353	330
Generic with a cost of $100 or more with >=200% increase	2	0	.	.	.	.	.	.

Total plan paid amount

- Definition: Dollar amount showing what health plans paid for each prescription drug within one year
- Data Field: Dollar amount per year
- Data Source: WA-APCD
- Methodology: Sum of the dollar amount paid to the provider by the health plan for each prescription drug in 2022

Total plan paid amount

Category	N Obs	N	Minimum	5th Pctl	Median	95th Pctl	Maximum	Mean
Biosimilar not at least 15% lower	9	5	$798	$798	$394,171	$1,583,807	$1,583,807	$519,697
Brand or biologic >= 15% increase	106	78	$44	$179	$19,169	$1,678,874	$2,838,401	$231,074
Brand or biologic >= 50% increase	21	15	$57	$57	$317,487	$3,939,760	$3,939,760	$740,689
Course of treatment $60,000 or more	331	226	$176	$1,901	$465,029	$53,215,570	$229,491,369	$8,415,818
Generic with a cost of $100 or more with >=200% increase	2	0	.	.	.	.	.	.

Average plan paid amount

- Definition: Dollar amount showing all the amount health plans paid for the prescription drug divided by the number of people who had a claim for that drug within one year
- Data Field: Dollar amount per person per year
- Data Source: WA-APCD



Average plan paid amount

Category	N Obs	N	Minimum	5th Pctl	Median	95th Pctl	Maximum	Mean
Biosimilar not at least 15% lower	9	5	$399	$399	$1,504	$26,364	$26,364	$10,879
Brand or biologic >= 15% increase	106	78	$10	$15	$2,147	$19,549	$177,400	$6,170
Brand or biologic >= 50% increase	21	15	$15	$15	$6,320	$177,400	$177,400	$19,700
Course of treatment $60,000 or more	331	226	$118	$456	$17,073	$117,638	$602,397	$37,828
Generic with a cost of $100 or more with >=200% increase	2	0	.	.	.	.	.	.

Total out-of-pocket cost

- Definition: Dollar amount showing patient paid amounts for the prescription drug. Out-of-pocket costs include deductibles, coinsurance, and copayments.
- Data Field: Dollar amount per year
- Data Source: WA-APCD
- Methodology: sum of total copay, coinsurance, and deductible amount for the prescription drug in 2022

Total out-of-pocket cost

Category	N Obs	N	Minimum	5th Pctl	Median	95th Pctl	Maximum	Mean
Biosimilar not at least 15% lower	9	5	$70	$70	$6,098	$230,591	$230,591	$56,711
Brand or biologic >= 15% increase	106	78	$0	$4	$1,748	$101,736	$295,086	$18,716
Brand or biologic >= 50% increase	21	15	$0	$0	$10,448	$197,862	$197,862	$28,265
Course of treatment $60,000 or more	331	226	$0	$0	$10,173	$1,312,495	$6,519,420	$236,862
Generic with a cost of $100 or more with >=200% increase	2	0	.	.	.	.	.	.

Average out-of-pocket cost

- Definition: Dollar amount showing patient paid amounts for the prescription drug divided by the number of people who had a claim for that drug within one year
- Data Field: Dollar amount per person per year
- Data Source: WA-APCD



Average out-of-pocket cost

Category	N Obs	N	Minimum	5th Pctl	Median	95th Pctl	Maximum	Mean
Biosimilar not at least 15% lower	9	5	$35	$35	$176	$678	$678	$275
Brand or biologic >= 15% increase	106	78	$0	$1	$50	$625	$3,142	$179
Brand or biologic >= 50% increase	21	15	$0	$0	$139	$3,142	$3,142	$416
Course of treatment $60,000 or more	331	226	$0	$0	$269	$2,672	$10,321	$778
Generic with a cost of $100 or more with >=200% increase	2	0	.	.	.	.	.	

Total paid amount

- Definition: Dollar amount showing the total amount paid by health plan and patients for each prescription drug within one year.
- Data Field: Dollar amount per year
- Data Source: WA-APCD
- Methodology: Sum of the total amount paid by health plan and patients for each prescription drug in 2022

Total paid amount

Category	N Obs	N	Minimum	5th Pctl	Median	95th Pctl	Maximum	Mean
Biosimilar not at least 15% lower	9	5	$868	$868	$400,384	$1,814,398	$1,814,398	$576,408
Brand or biologic >= 15% increase	106	78	$57	$446	$23,555	$1,761,230	$2,888,668	$249,790
Brand or biologic >= 50% increase	21	15	$57	$57	$319,960	$3,961,907	$3,961,907	$768,954
Course of treatment $60,000 or more	331	226	$176	$1,901	$485,212	$53,444,070	$236,010,789	$8,652,680
Generic with a cost of $100 or more with >=200% increase	2	0	.	.	.	.	.	.

Average paid amount

- Definition: Dollar amount showing the total amount paid by health plan and patients for each prescription drug divided by the number of people who had a claim for that drug within one year.
- Data Field: Dollar amount per person per year
- Data Source: WA-APCD



Average paid amount

Category	N Obs	N	Minimum	5th Pctl	Median	95th Pctl	Maximum	Mean
Biosimilar not at least 15% lower	9	5	$434	$434	$1,664	$26,692	$26,692	$11,154
Brand or biologic >= 15% increase	106	78	$15	$35	$2,220	$19,578	$180,542	$6,349
Brand or biologic >= 50% increase	21	15	$19	$19	$6,404	$180,542	$180,542	$20,116
Course of treatment $60,000 or more	331	226	$165	$507	$17,339	$119,352	$604,024	$38,606
Generic with a cost of $100 or more with >=200% increase	2	0	.	.	.	.	.	.

Patient liability proportion

- Definition: Proportion showing the share of the total amount that a patient pays towards the total amount paid by health plan and patients for each prescription drug within one year
- Data Field: Proportion
- Data Source: WA-APCD



Patient liability proportion

Category	N Obs	N	Minimum	5th Pctl	Median	95th Pctl	Maximum	Mean
Biosimilar not at least 15% lower	9	5	1.2%	1.2%	8.1%	12.7%	12.7%	6.9%
Brand or biologic >= 15% increase	106	78	0.0%	0.0%	6.7%	55.5%	66.9%	13.6%
Brand or biologic >= 50% increase	21	15	0.0%	0.0%	2.1%	55.0%	55.0%	7.5%
Course of treatment $60,000 or more	331	226	0.0%	0.0%	2.7%	15.0%	60.3%	4.2%
Generic with a cost of $100 or more with >=200% increase	2	0	.	.	.	.	.	

Therapeutic equivalent availability

- Definition: Therapeutic equivalence is determined by such factors as having the same ingredient(s) in the same concentration with the same pharmacokinetics (the way the body absorbs, distributes, metabolizes, and eliminates the drug). If any of these factors differ, the drugs are not substitutable.
- Data Field: Binary, Yes/No
- Data Source: First Databank (FDB)
- Methodology: Retrieve a list of therapeutically equivalent products using Orange Book following FDB Therapeutic Substitution Retrieval Method or determine whether a biological product has biosimilar using FDB. If the biological product has a biosimilar, it is also considered as having a therapeutic equivalent

Generic availability

- Definition: The Generic drug has the same active chemical ingredient, dosage strength, and dosage form as the brand name drug.
- Data Field: Binary, Yes/No
- Data Source: First Databank (FDB)
- Methodology: Retrieve generics to brand by gcn_seqno or by gpi14

If the drug meets multiple thresholds of the legislative definition

- Definition: Whether the drug in the eligible drug list meets multiple thresholds of the legislative definition
- Data Field: When list_count>1
- Data Source: Eligible drug list
- Methodology: The prescription drug is in multiple eligible drug categories.

If the drug meets multiple thresholds of the legislative definition



Prioritized Data Measures For Selecting Drugs for Affordability Review

Washington State Health Care Authority

Deciding Whether To Conduct A Review

6 selection criteria were prioritized:

If the drug meets multiple thresholds of the legislative definition



Therapeutic equivalent availability/ Generic availability

Rank the Eligible Drugs

Washington State Health Care Authority

Colorado PDAB Eligible Drug Dashboard ranking and weighting method

Washington State Health Care Authority

Colorado PDAB 2023 Eligible Drug Dashboard

Prioritized Ranked & Weighted List: Drugs 1 - 20 sorted by Prioritized Rank

Brand Name	Strength	Dosage Form	Prioritized Rank	Patient Count	Change in WAC	Patient OOP Cost	Total Paid	Avg Paid PPPY
HUMIRA	40 mg/0.4 mL	PEN INJECTOR ..	1	3,703	42.09%	$2,982	$191,201,943	$25,817
TRIKAFTA	100 mg-50 mg-75 mg (day..	TABLET SEQUE..	2	372	4.90%	$1,732	$75,859,910	$203,924
ENBREL	50 mg/mL (1 mL)	PEN INJECTOR ..	3	1,707	36.24%	$2,812	$72,504,276	$42,475
STELARA	90 mg/mL	SYRINGE (ML)	4	414	23.87%	$1,399	$45,794,896	$61,969
HUMIRA	40 mg/0.4 mL	SYRINGE KIT (E..	5	643	42.09%	$2,556	$32,600,235	$50,700
GENVOYA	150 mg-150 mg-200 mg-1..	TABLET	6	940	28.84%	$1,293	$27,344,595	$29,090
AUBAGIO	14 mg	TABLET	7	335	23.64%	$4,207	$23,428,771	$69,937
GILENYA	0.5 mg	CAPSULE	8	282	32.66%	$3,367	$22,855,252	$81,047
XTANDI	40 mg	CAPSULE	9	282	19.21%	$3,078	$21,648,442	$76,768
REVLIMID	10 mg	CAPSULE	10	167	25.80%	$3,232	$20,056,441	$125,436
IMBRUVICA	420 mg	TABLET	11	166	39.72%	$3,308	$19,490,114	$117,410
ENBREL	50 mg/mL (1 mL)	SYRINGE (ML)	12	460	36.24%	$2,709	$18,661,606	$22,465
COSENTYX	150 mg/mL	PEN INJECTOR ..	13	456	46.94%	$2,168	$17,954,496	$39,335
TAKHZYRO	300 mg/2 mL (150 mg/mL)	VIAL (ML)	14	42	12.55%	$4,999	$16,557,876	$394,235
IBRANCE	125 mg	TABLET	15	213	21.11%	$1,862	$15,846,952	$74,399

https://public.tableau.com/app/profile/colorado.division.of.insurance/viz/COPDAB2023EligibleDrugDashboard/0_Navigation?publish=yes

Weighting

Result of criteria ranking

	Member 1	Member 2	Member 3	Member 4		
	Sami Diab	Amy Gutierrez	Gail Mizner	Justin VandenBerg	Sum	Rank
WAC Pricing Change	1	4	4	4	13	2
Total Paid Amount	4	1	2	2	9	4
Avg Paid Per Person Per Year	3	2	1	1	7	5
Patient OOP Per Person Per Year	2	3	3	3	11	3
Total Utilization	5	5	5	5	20	1

Relative weights

	Member 1	Member 2	Member 3	Member 4	
	Sami Diab	Amy Gutierrez	Gail Mizner	Justin VandenBerg	Average
How much more important is #4 compared to #5?	25%	0%	0%	0%	6.25%
How much more important is #3 compared to #4?	5%	50%	20%	5%	20.00%
How much more important is #2 compared to #3?	40%	10%	20%	0%	17.50%
How much more important is #1 compared to #2?	1%	20%	25%	5%	12.75%

Weights

B	C	D	G
Rank	Value element	weight	Basic Normalized
#1	Total Utilization		25.9%
#2	WAC Pricing Change	12.8%	23.0%
#3	Patient OOP Per Person Per Year	17.5%	19.5%
#4	Total Paid Amount	20.0%	16.3%
#5	Avg Paid Per Person Per Year	6.3%	15.3%
#6			

Ranking

Drug	Patient Count	Change in WAC	OOP Cost	Total Paid	Avg Paid PPPY
Humira 40 mg/0.4mL Pen injector Kit	3,703	42.09%	$2,982	$191,201,943	$25,817
Enbrel 50 mg/mL (1 mL) Pen injector	1,707	36.24%	$2,812	$72,504,276	$42,475

Weights

B	C	D	G
Rank	Value element	weight	Basic Normalized
#1	Total Utilization		25.9%
#2	WAC Pricing Change	12.8%	23.0%
#3	Patient OOP Per Person Per Year	17.5%	19.5%
#4	Total Paid Amount	20.0%	16.3%
#5	Avg Paid Per Person Per Year	6.3%	15.3%
#6			

- Humira 40 mg/0.4mL Pen injector Kit, the score is calculated as: (3703*.25888)+(.4209*.22961)+(2982*.19541)+(191201743*.16284)+(25817*.15326) = 31,140,822.55

- Enbrel 50 mg/mL (1 mL) Pen injector, the score is calculated as: (1707*.25888)+(.3624*.22961)+(2812*.19541)+(72504276*.16284)+(42475*.15326) = 11,814,098.51

Method 1: Sort the drug list by the selected data measures sequentially (Example 1)



Method 1: Sort the drug list by the selected data measures sequentially (Example 1)

hasgen	hasther	therapeutic_	plan_paid_amt	mbr_paid_amt	mbr_count_n	avg_plan_paid_amt	avg_mbr_paid_amt	paid_amt	avg_paid_amt	patient_liability
no	no	ANTISERA	760,809.04	41,285.25		190,202.26	10,321.31	802,094.29	200,523.57	0.051471816
yes	yes	ANTINEOPLA	626,769.04	21,221.90		156,692.26	5,305.48	647,990.94	161,997.74	0.032750304
yes	yes	ANTINEOPLA	523,558.12	29,883.30		87,259.69	4,980.55	553,441.42	92,240.24	0.053995417
no	no	ANTINEOPLA	44,318,385.38	1,850,000.38	372	119,135.44	4,973.12	46,168,385.76	124,108.56	0.040070718
no	no	ANTINEOPLA	54,127,828.79	2,350,731.27	553	97,880.34	4,250.87	56,478,560.06	102,131.21	0.041621657
no	no	ANTINEOPLA	17,396,813.72	843,372.16	228	76,301.81	3,699.00	18,240,185.88	80,000.82	0.046237038
yes	yes	ANTINEOPLA	382,605.53	25,423.73		54,657.93	3,631.96	408,029.26	58,289.89	0.062308595
no	no	ANTINEOPLA	30,274,644.11	1,312,494.88	412	73,482.15	3,185.67	31,587,138.99	76,667.81	0.041551559
yes	yes	ANTINEOPLA	196,781.47	6,353.42		98,390.74	3,176.71	203,134.89	101,567.45	0.031276853
no	no	ANTINEOPLA	17,017,434.13	655,420.32	208	81,814.59	3,151.06	17,672,854.45	84,965.65	0.037086274
no	no	ANTINEOPLA	132,408,663.94	4,869,808.86	1552	85,314.86	3,137.76	137,278,472.80	88,452.62	0.035473944
yes	yes	ANTI-ARTHRI	437,639.46	8,015.04		145,879.82	2,671.68	445,654.50	148,551.50	0.017984874
no	no	ANTINEOPLA	7,640,425.30	286,166.09	111	68,832.66	2,578.07	7,926,591.39	71,410.73	0.036102036
no	no	ANTI-INFLAM	5,003,229.22	192,948.52	76	65,831.96	2,538.80	5,196,177.74	68,370.76	0.037132779
yes	yes	SOMATOSTA	3,034,009.84	91,319.72	38	79,842.36	2,403.15	3,125,329.56	82,245.51	0.029219229
yes	yes	ANTINEOPLA	1,043,478.80	61,201.06	26	40,133.80	2,353.89	1,104,679.86	42,487.69	0.055401626
no	no	ANTINEOPLA	14,423,506.58	419,406.19	191	75,515.74	2,195.84	14,842,912.77	77,711.59	0.028256327
no	no	ANTINEOPLA	343,873.19	10,898.81		68,774.64	2,179.76	354,772.00	70,954.40	0.030720604
no	no	ANTINEOPLA	14,531,418.62	423,013.23	197	73,763.55	2,147.28	14,954,431.85	75,910.82	0.028286814

Blank cell: Less than 10

Method 1: Sort the drug list by the selected data measures sequentially (Example 2)



Method 1: Sort the drug list by the selected data measures sequentially (Example 2)

1 2 3

hasgen	hasther	therapeutic_class	plan_paid_amt	mbr_paid_amt	mbr_count_n	avg_plan_paid_	avg_mbr_paid_amt	paid_amt	avg_paid_amt	patient_liability
no	no	PANCREATIC ENZY	64,711,704.46	1,654,034.87	7353	8,800.72	224.95	66,365,739.33	9,025.67	0.024923023
no	no	GLUCOCORTICOID	3,860,767.39	1,090,243.86	5467	706.19	199.42	4,951,011.25	905.62	0.220206298
no	no	ANTI-INFLAMMATO	229,491,368.53	6,519,420.22	4841	47,405.78	1,346.71	236,010,788.75	48,752.49	0.027623399
no	no	ANTIPSYCHOTIC-A	26,194,117.91	810,025.94	4826	5,427.71	167.85	27,004,143.85	5,595.55	0.029996357
no	no	ANTIPSYCHOTIC,A	53,215,570.31	228,499.70	4552	11,690.59	50.20	53,444,070.01	11,740.79	0.004275492
no	no	GLUCOCORTICOID	1,865,320.06	471,923.63	3377	552.36	139.75	2,337,243.69	692.11	0.201914602
no	no	PANCREATIC ENZY	9,151,441.56	579,279.87	3079	2,972.21	188.14	9,730,721.43	3,160.35	0.05953103
no	yes	ANTI-INFLAMMATO	153,446,778.52	4,012,017.29	2760	55,596.66	1,453.63	157,458,795.81	57,050.29	0.025479792
no	no	ANTIPSYCHOTICS,	15,810,183.16	413,769.75	2403	6,579.35	172.19	16,223,952.91	6,751.54	0.025503634
no	no	PANCREATIC ENZY	20,719,195.55	460,069.66	2326	8,907.65	197.79	21,179,265.21	9,105.45	0.021722645
no	no	PANCREATIC ENZY	14,374,518.83	378,416.35	1948	7,379.12	194.26	14,752,935.18	7,573.38	0.025650241
no	no	JANUS KINASE (JA	68,806,859.86	1,974,654.26	1831	37,578.84	1,078.46	70,781,514.12	38,657.30	0.027897881
no	no	ANTINEOPLASTIC -	132,408,663.94	4,869,808.86	1552	85,314.86	3,137.76	137,278,472.80	88,452.62	0.035473944
no	no	ANTIPSYCHOTICS,	8,041,149.18	239,009.41	1432	5,615.33	166.91	8,280,158.59	5,782.23	0.028865318
no	no	ANTI-INFLAMMATO	66,712,780.72	2,036,512.34	1356	49,198.22	1,501.85	68,749,293.06	50,700.07	0.029622302
no	no	ANTIPSORIATIC AG	64,358,611.80	1,708,775.42	1326	48,535.91	1,288.67	66,067,387.22	49,824.58	0.025864129
no	no	PANCREATIC ENZY	1,783,873.63	177,310.43	1322	1,349.37	134.12	1,961,184.06	1,483.50	0.090409887
yes	no	HEP C VIRUS-NS5B	76,950,394.23	1,630,589.15	1262	60,974.96	1,292.07	78,580,983.38	62,267.02	0.020750429
no	no	ANTIPSYCHOTIC,A	11,825,060.66	63,001.17	1148	10,300.58	54.88	11,888,061.83	10,355.45	0.005299532

Method 2: Sort the most important data measure, and then look at the rank of the other data measures (Example 1)

	plan_paid_amt	mbr_paid_amt	mbr_count_n	avg_plan_paid_amt
1	$64,711,704.46	$1,654,034.87	7353	$8,800.72
2	$3,860,767.39	$1,090,243.86	5467	$706.19
3	$229,491,368.53	$6,519,420.22	4841	$47,405.78
4	$26,194,117.91	$810,025.94	4826	$5,427.71
5	$53,215,570.31	$228,499.70	4552	$11,690.59
6	$1,865,320.06	$471,923.63	3377	$552.36
7	$9,151,441.56	$579,279.87	3079	$2,972.21
8	$153,446,778.52	$4,012,017.29	2760	$55,596.66
9	$15,810,183.16	$413,769.75	2403	$6,579.35
10	$20,719,195.55	$460,069.66	2326	$8,907.65
11	$14,374,518.83	$378,416.35	1948	$7,379.12
12	$68,806,859.86	$1,974,654.26	1831	$37,578.84
13	$132,408,663.94	$4,869,808.86	1552	$85,314.86
14	$8,041,149.18	$239,009.41	1432	$5,615.33
15	$66,712,780.72	$2,036,512.34	1356	$49,198.22
16	$64,358,611.80	$1,708,775.42	1326	$48,535.91
17	$1,783,873.63	$177,310.43	1322	$1,349.37
18	$76,950,394.23	$1,630,589.15	1262	$60,974.96
19	$11,825,060.66	$63,001.17	1148	$10,300.58
20	$37,838,246.51	$1,052,105.24	1109	$34,119.25
21	$34,960,548.27	$1,043,991.81	969	$36,079.00
22	$37,553,411.00	$1,096,323.12	906	$41,449.68
23	$67,578,035.84	$1,450,857.74	817	$82,714.85
24	$2,390,450.92	$109,022.39	817	$2,925.89
25	$58,470,930.48	$1,008,934.98	716	$81,663.31
26	$533,727.65	$93,930.30	651	$819.86
27	$45,301,688.50	$769,048.56	593	$76,394.08
28	$14,602,340.16	$553,825.70	576	$25,351.29
29	$3,219,349.80	$74,996.38	556	$5,790.20
30	$54,127,828.79	$2,350,731.27	553	$97,880.34
31	$18,784,314.71	$560,124.71	520	$36,123.68
32	$1,224,741.04	$33,208.74	460	$2,662.48
33	$30,274,644.11	$1,312,494.88	412	$73,482.15
34	$16,455,657.71	$548,646.00	402	$40,934.47
35	$18,390,714.33	$505,117.56	395	$46,558.77
36	$8,396,152.19	$210,342.91	386	$21,751.69
37	$44,318,385.38	$1,850,000.38	372	$119,135.44
38	$21,734,567.91	$416,853.78	327	$66,466.57
39	$1,622,756.68	$37,467.27	306	$5,303.13
40	$1,706,749.04	$66,710.98	287	$5,946.86

Method 2: Sort the most important data measure, and then look at the rank of the other data measures (Example 1)

avg_mbr_paid_amt	paid_amt	avg_paid_amt	patient_liability	increase_n	Rank for Variable avg_mbr_paid_amt	Rank for Variable paid_amt	sum_of_ranks
$224.95	$66,365,739.33	$9,025.67	2.49%	.	125	8	133
$199.42	$4,951,011.25	$905.62	22.02%	.	130	52	182
$1,346.71	$236,010,788.75	$48,752.49	2.76%	.	48	1	49
$167.85	$27,004,143.85	$5,595.55	3.00%	.	144	20	164
$50.20	$53,444,070.01	$11,740.79	0.43%	.	187	12	199
$139.75	$2,337,243.69	$692.11	20.19%	.	157	66	223
$188.14	$9,730,721.43	$3,160.35	5.95%	.	134	42	176
$1,453.63	$157,458,795.81	$57,050.29	2.55%	.	40	2	42
$172.19	$16,223,952.91	$6,751.54	2.55%	.	141	29	170
$197.79	$21,179,265.21	$9,105.45	2.17%	.	132	22	154
$194.26	$14,752,935.18	$7,573.38	2.57%	.	133	33	166
$1,078.46	$70,781,514.12	$38,657.30	2.79%	.	63	5	68
$3,137.76	$137,278,472.80	$88,452.62	3.55%	.	11	3	14
$166.91	$8,280,158.59	$5,782.23	2.89%	.	145	45	190
$1,501.85	$68,749,293.06	$50,700.07	2.96%	.	36	7	43
$1,288.67	$66,067,387.22	$49,824.58	2.59%	.	52	9	61
$134.12	$1,961,184.06	$1,483.50	9.04%	.	161	72	233
$1,292.07	$78,580,983.38	$62,267.02	2.08%	.	51	4	55
$54.88	$11,888,061.83	$10,355.45	0.53%	.	185	36	221
$948.70	$38,890,351.75	$35,067.95	2.71%	.	70	16	86
$1,077.39	$36,004,540.08	$37,156.39	2.90%	.	64	18	82
$1,210.07	$38,649,734.12	$42,659.75	2.84%	.	57	17	74
$1,775.84	$69,028,893.58	$84,490.69	2.10%	.	29	6	35
$133.44	$2,499,473.31	$3,059.33	4.36%	.	162	64	226
$1,409.13	$59,479,865.46	$83,072.44	1.70%	.	44	10	54
$144.29	$627,657.95	$964.14	14.97%	.	155	105	260
$1,296.88	$46,070,737.06	$77,690.96	1.67%	.	50	15	65
$961.50	$15,156,165.86	$26,312.79	3.65%	.	69	30	99
$134.89	$3,294,346.18	$5,925.08	2.28%	.	160	59	219
$4,250.87	$56,478,560.06	$102,131.21	4.16%	.	5	11	16
$1,077.16	$19,344,439.42	$37,200.85	2.90%	.	65	24	89
$72.19	$1,257,949.78	$2,734.67	2.64%	.	178	87	265
$3,185.67	$31,587,138.99	$76,667.81	4.16%	.	8	19	27
$1,364.79	$17,004,303.71	$42,299.26	3.23%	.	47	28	75
$1,278.78	$18,895,831.89	$47,837.55	2.67%	.	53	25	78
$544.93	$8,606,495.10	$22,296.62	2.44%	.	87	44	131
$4,973.12	$46,168,385.76	$124,108.56	4.01%	.	4	14	18
$1,274.78	$22,151,421.69	$67,741.35	1.88%	.	54	21	75
$122.44	$1,660,223.95	$5,425.57	2.26%	.	169	77	246
$232.44	$1,773,460.02	$6,179.30	3.76%	.	121	75	196

Method 3: Sort prioritized data measures individually, then look at the sum of the rank of the data measures (Example)

	plan_paid_amt	mbr_paid_amt	mbr_count_n	avg_plan_paid_amt	avg_mbr_paid_amt	paid_amt
1	$132,408,663.94	$4,869,808.86	1552	$85,314.86	$3,137.76	$137,278,472.80
2	$54,127,828.79	$2,350,731.27	553	$97,880.34	$4,250.87	$56,478,560.06
3	$153,446,778.52	$4,012,017.29	2760	$55,596.66	$1,453.63	$157,458,795.81
4	$229,491,368.53	$6,519,420.22	4841	$47,405.78	$1,346.71	$236,010,788.75
5	$44,318,385.38	$1,850,000.38	372	$119,135.44	$4,973.12	$46,168,385.76
6	$66,712,780.72	$2,036,512.34	1356	$49,198.22	$1,501.85	$68,749,293.06
7	$67,578,035.84	$1,450,857.74	817	$82,714.85	$1,775.84	$69,028,893.58
8	$30,274,644.11	$1,312,494.88	412	$73,482.15	$3,185.67	$31,587,138.99
9	$76,950,394.23	$1,630,589.15	1262	$60,974.96	$1,292.07	$78,580,983.38
10	$64,358,611.80	$1,708,775.42	1326	$48,535.91	$1,288.67	$66,067,387.22
11	$68,806,859.86	$1,974,654.26	1831	$37,578.84	$1,078.46	$70,781,514.12
12	$17,396,813.72	$843,372.16	228	$76,301.81	$3,699.00	$18,240,185.88
13	$58,470,930.48	$1,008,934.98	716	$81,663.31	$1,409.13	$59,479,865.46
14	$17,017,434.13	$655,420.32	208	$81,814.59	$3,151.06	$17,672,854.45
15	$37,553,411.00	$1,096,323.12	906	$41,449.68	$1,210.07	$38,649,734.12
16	$45,301,688.50	$769,048.56	593	$76,394.08	$1,296.88	$46,070,737.06
17	$34,960,548.27	$1,043,991.81	969	$36,079.00	$1,077.39	$36,004,540.08
18	$37,838,246.51	$1,052,105.24	1109	$34,119.25	$948.70	$38,890,351.75
19	$14,531,418.62	$423,013.23	197	$73,763.55	$2,147.28	$14,954,431.85
20	$13,414,914.55	$444,664.25	244	$54,979.16	$1,822.39	$13,859,578.80
21	$16,455,657.71	$548,646.00	402	$40,934.47	$1,364.79	$17,004,303.71
22	$14,423,506.58	$419,406.19	191	$75,515.74	$2,195.84	$14,842,912.77
23	$13,789,943.35	$431,255.02	212	$65,046.90	$2,034.22	$14,221,198.37
24	$19,821,323.56	$349,124.64	169	$117,285.94	$2,065.83	$20,170,448.20
25	$18,390,714.33	$505,117.56	395	$46,558.77	$1,278.78	$18,895,831.89
26	$18,784,314.71	$560,124.71	520	$36,123.68	$1,077.16	$19,344,439.42
27	$64,711,704.46	$1,654,034.87	7353	$8,800.72	$224.95	$66,365,739.33
28	$52,352,462.80	$223,144.26	123	$425,629.78	$1,814.18	$52,575,607.06
29	$21,734,567.91	$416,853.78	327	$66,466.57	$1,274.78	$22,151,421.69
30	$9,960,767.09	$416,749.41	270	$36,891.73	$1,543.52	$10,377,516.50
31	$14,602,340.16	$553,825.70	576	$25,351.29	$961.50	$15,156,165.86
32	$10,339,928.08	$313,543.18	154	$67,142.39	$2,035.99	$10,653,471.26
33	$10,065,652.29	$331,804.32	197	$51,094.68	$1,684.29	$10,397,456.61
34	$7,640,425.30	$286,166.09	111	$68,832.66	$2,578.07	$7,926,591.39
35	$9,337,544.66	$220,212.26	123	$75,915.00	$1,790.34	$9,557,756.92
36	$26,194,117.91	$810,025.94	4826	$5,427.71	$167.85	$27,004,143.85
37	$5,003,229.22	$192,948.52	76	$65,831.96	$2,538.80	$5,196,177.74
38	$20,719,195.55	$460,069.66	2326	$8,907.65	$197.79	$21,179,265.21
39	$3,860,767.39	$1,090,243.86	5467	$706.19	$199.42	$4,951,011.25
40	$9,612,905.86	$203,293.70	220	$43,695.03	$924.06	$9,816,199.56

Method 3: Sort prioritized data measures individually, then look at the sum of the rank of the data measures (Example)

Rank for Variable mbr_count_n	Rank for Variable avg_mbr_paid_amt	Rank for Variable mbr_paid_amt	Rank for Variable paid_amt	sum_of_ranks
13	11	2	3	29
30	5	4	11	50
8	40	3	2	53
3	48	1	1	53
37	4	7	14	62
15	36	5	7	63
23.5	29	11	6	69.5
33	8	12	19	72
18	51	10	4	83
16	52	8	9	85
12	63	6	5	86
46	6	18	26	96
25	44	17	10	96
50	10	21	27	108
22	57	13	17	109
27	50	20	15	112
21	64	16	18	119
20	70	15	16	121
51.5	19	31	31	132.5
44	25	29	35	133
34	47	25	28	134
53	17	32	32	134
48.5	23	30	34	135.5
56	21	37	23	137
35	53	26	25	139
31	65	23	24	143
1	125	9	8	143
62.5	26	43	13	144.5
38	54	33	21	146
42	35	34	40	151
28	69	24	30	151
57	22	39	37	155
51.5	31	38	39	159.5
65	13	40	46	164
62.5	28	44	43	177.5
4	144	19	20	187
76.5	14	47	50	187.5
10	132	28	22	192
2	130	14	52	198
47	71	46	41	205

WA PDAB Eligible Drug Dashboard Preview

Washington State Health Care Authority

WA PDAB Eligible Drug Dashboard Preview

Background | 2023 Eligible Drugs - Summary | Drug Lookup | Drugs on Multiple Lists

2023 Eligible Drugs Summary

Washington State Health Care Authority

Category	Count of NDC	% of Total
Biosimilar not at least 15% lower	9	1.98%
Brand or biologic ≥ 15% increase	106	23.30%
Brand or biologic ≥ 50% increase	21	4.62%
Course of treatment $60,000 or more	331	72.75%
Generic with a cost of $100 or more with ≥ 200% increase	2	0.44%
Total Eligible	455	100.00%

Eligible Drugs by Cost - Course of Treatment $60k or more



Top Drugs by Member Count 10

Total Number of People Using the Drug

Top Drugs by Member Count	Max. NDC	Label Name	Generic Name	Category	
Top 10 Drugs	43386009019	GAVILYTE-G SOLUTION	peg 3350/sod sulf/sod bicarb/sod chloride/potassium chloride	Brand or biologic ≥ 15% increase	67,355
	43386006019	GAVILYTE-C SOLUTION	peg 3350/sod sulf/sod bicarb/sod chloride/potassium chloride	Brand or biologic ≥ 15% increase	41,939
				Brand or biologic ≥ 50% increase	41,939
	00032301628	CREON DR 36,000 UNIT CAPSULE	lipase/protease/amylase	Course of treatment $60,000 or more	7,353
		PULMICORT 180 MCG	budesonide	Course of treatment	

Top Drugs by Total Paid Amount 10

Total Paid Amount

Top Drugs by Total Paid A..	NDC	Label Name	Generic Name	Category	
Top 10 Drugs	58406003204	ENBREL 50 MG/ML SURECLICK	etanercept	Course of treatment $60,000 or more	$236,010,789
	00074433902	HUMIRA PEN 40 MG/0.8 ML	adalimumab	Course of treatment $60,000 or more	$157,458,796
	00469012599	XTANDI 40 MG CAPSULE	enzalutamide	Course of treatment $60,000 or more	$137,278,473
	61958220101	EPCLUSA 400 MG-100 MG TABLET	sofosbuvir/velpatasvir	Course of treatment $60,000 or more	$78,580,983
	00069050130	XELJANZ XR 11 MG TABLET	tofacitinib citrate	Course of treatment	$70,781,514

WA PDAB Eligible Drug Dashboard Preview



WA PDAB Eligible Drug Dashboard Preview

Drugs on Multiple Lists

Washington State Health Care Authority

Drugs on Multiple Lists

14 NDCs are on multiple lists.

NDC	Label Name	Generic Name	Category	Type	Generic	Biosimilar	Therapeutic Equivalent
00310080039	TUDORZA PRESSAIR 400 MCG INHAL	aclidinium bromide	Brand or biologic ≥ 15% increase	brand	No	No	No
			Brand or biologic ≥ 50% increase	brand	No	No	No
00310080060	TUDORZA PRESSAIR 400 MCG INHAL	aclidinium bromide	Brand or biologic ≥ 15% increase	brand	No	No	No
			Brand or biologic ≥ 50% increase	brand	No	No	No
43386006019	GAVILYTE-C SOLUTION	peg 3350/sod sulf/sod bicarb/sod chloride/potassium chloride	Brand or biologic ≥ 15% increase	brand	No	No	No
			Brand or biologic ≥ 50% increase	brand	No	No	No
50742051330	NITRO-DUR 0.1 MG/HR PATCH	nitroglycerin	Brand or biologic ≥ 15% increase	brand	Yes	No	No
			Brand or biologic ≥ 50% increase	brand	Yes	No	No
50742051430	NITRO-DUR 0.2 MG/HR PATCH	nitroglycerin	Brand or biologic ≥ 15% increase	brand	Yes	No	No
			Brand or biologic ≥ 50% increase	brand	Yes	No	No
50742051530	NITRO-DUR 0.3 MG/HR PATCH	nitroglycerin	Brand or biologic ≥ 15% increase	brand	No	No	No
			Brand or biologic ≥ 50% increase	brand	No	No	No
50742051630	NITRO-DUR 0.4 MG/HR PATCH	nitroglycerin	Brand or biologic ≥ 15% increase	brand	Yes	No	No
			Brand or biologic ≥ 50% increase	brand	Yes	No	No
50742051730	NITRO-DUR 0.6 MG/HR PATCH	nitroglycerin	Brand or biologic ≥ 15% increase	brand	Yes	No	No
			Brand or biologic ≥ 50% increase	brand	Yes	No	No
50742051830	NITRO-DUR 0.8 MG/HR PATCH	nitroglycerin	Brand or biologic ≥ 15% increase	brand	No	No	No
			Brand or biologic ≥ 50% increase	brand	No	No	No
51267089099	CONTRAVE ER 8-90 MG TABLET	naltrexone HCl/bupropion HCl	Brand or biologic ≥ 15% increase	brand	No	No	No
			Brand or biologic ≥ 50% increase	brand	No	No	No
69784042012	LOVAZA 1 GM CAPSULE	omega-3 acid ethyl esters	Brand or biologic ≥ 15% increase	brand	Yes	No	Yes
			Brand or biologic ≥ 50% increase	brand	Yes	No	Yes
71090000101	KEVEYIS 50 MG TABLET	dichlorphenamide	Brand or biologic ≥ 15% increase	brand	No	No	Yes
			Brand or biologic ≥ 50% increase	brand	No	No	Yes
72245019303	NALOCET 2.5-300 MG TABLET	oxycodone HCl/acetaminophen	Brand or biologic ≥ 15% increase	brand	Yes	No	No
			Brand or biologic ≥ 50% increase	brand	Yes	No	No
76336008060	LYSODREN 500 MG TABLET	mitotane	Brand or biologic ≥ 15% increase	brand	No	No	No
			Course of treatment $60,000 or more	brand	No	No	No

Next Steps



Finalize data measures to be used for selecting prescription drugs for affordability review



Finalize methodology used for selecting prescription drugs for affordability review



Modify dashboard of eligible prescription drugs and chosen data measures

Select prescription drugs for drug affordability review

Discussion and Questions

Washington State Health Care Authority